Prospective, Open-label, Multi-cohort Study of Becotatug Vedotin With Tislelizumab and Chemotherapy in Esophageal Squamous Cell Carcinoma - Phase 2

Clinical trial NCT07531979 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07531979
Sponsor: Tianjin Medical University Cancer Institute and Hospital
Status: NOT_YET_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

ESCC Tislelizumab Chemotherapy Becotatug Vedotin EGFR ADC PD-1 Inhibitor

Start date: 2026-04-01
Primary completion: 2027-03-31
Enrollment: 93

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.